Skip to main content
Medical information Clinical review pending

Genetic Testing

ERLIN2 Gene SPG18 Genetic Test

Genetic test using Next-Generation Sequencing (NGS) to analyze the ERLIN2 gene for variations linked to neurological disorders like hereditary spastic paraplegia (HSP).

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required for a blood draw. Confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the ERLIN2 Gene SPG18 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with symptoms suggestive of hereditary spastic paraplegia (HSP).
  • ✓Patients with a family history of HSP or related neurological disorders.
  • ✓Individuals seeking to understand the genetic cause of their neurological symptoms.
  • ✓Cases where previous genetic testing was inconclusive.
  • ✓Genetic counseling and family planning for individuals with a known ERLIN2 mutation.
02

In plain language

What this test helps you understand

This test helps identify specific genetic variations in the ERLIN2 gene that are associated with hereditary spastic paraplegia (HSP) and other neurological disorders. It can aid in confirming a diagnosis, understanding the genetic basis of symptoms, and informing family planning and genetic counseling.
The ERLIN2 Gene SPG18 NGS Genetic DNA Test is a diagnostic tool used to identify genetic mutations associated with certain neurological disorders. This test utilizes advanced Next-Generation Sequencing (NGS) technology to thoroughly analyze the ERLIN2 gene. Understanding variations in this gene can provide important insights into the genetic causes of neurological conditions. This test specifically looks for changes in the ERLIN2 gene that may be linked to hereditary spastic paraplegia (HSP) and related neurological symptoms. Discussing the test with a healthcare provider is recommended to determine if it is appropriate for your situation.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required for a blood draw. Confirm with the laboratory before booking.
SampleBlood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
MethodologyNext-Generation Sequencing (NGS) is used to analyze the ERLIN2 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes the ERLIN2 gene specifically. It will not detect mutations in other genes that can cause similar neurological conditions. The test may not identify all possible ERLIN2 gene variants. Results should be interpreted in the context of the patient's clinical presentation and family history. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The ERLIN2 gene provides instructions for making a protein important for the health of nerve cells. Variations in this gene are linked to certain neurological disorders.
HSP is a group of inherited disorders characterized by progressive stiffness (spasticity) and weakness in the legs.
This test is typically recommended for individuals with symptoms of HSP or a family history of the condition, after consultation with a healthcare provider.
Results are provided in a detailed report. It is crucial to discuss the report with your doctor or a genetic counselor to understand the findings.
Yes, genetic counseling is highly recommended before and after testing to discuss the implications of the test and its results.
A blood sample, extracted DNA, or a single drop of blood on an FTA card is required for this test.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp